BridgeBio to Participate in the J.P. Morgan Healthcare Conference Jan 5, 2026 07:30AM
BridgeBio's acoramidis shows mortality benefit in ATTR-CM variant patients Nov 10, 2025 02:33AM
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations Nov 8, 2025 10:41AM
BridgeBio to report phase 3 encaleret results for rare disease wednesday Oct 28, 2025 04:01PM
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th Oct 28, 2025 04:01PM
View Older Stories

Oct 24, 2025 04:01PM BridgeBio schedules calls for LGMD2I/R9 trial results and Q3 earnings
Oct 24, 2025 04:01PM BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
Oct 3, 2025 04:01PM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sep 28, 2025 11:15AM Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
Sep 22, 2025 07:30AM BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
Sep 10, 2025 04:01PM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sep 6, 2025 02:30PM BridgeBio reports positive encaleret results for hypoparathyroidism
Sep 6, 2025 02:30PM Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
Sep 3, 2025 07:30AM BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
Sep 2, 2025 07:30AM BridgeBio to present encaleret phase 2 data at ASBMR meeting
Sep 2, 2025 07:30AM BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
Aug 30, 2025 07:15AM Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
Aug 27, 2025 07:30AM BridgeBio to Participate in September Investor Conferences
Aug 25, 2025 07:30AM BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
Aug 5, 2025 04:01PM BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
Jul 23, 2025 07:31AM BridgeBio study finds ADH1 genetic condition underdiagnosed by 80%
Jul 23, 2025 07:30AM Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
Jul 22, 2025 07:30AM BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
Jun 30, 2025 07:30AM BridgeBio Pharma (BBIO) Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty
Jun 30, 2025 07:30AM BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
Jun 26, 2025 07:30AM BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
Jun 2, 2025 07:30AM BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
May 20, 2025 07:30AM Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
May 19, 2025 12:37PM BridgeBio Pharma Inc. (BBIO): Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
May 19, 2025 12:33PM Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
May 14, 2025 04:01PM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 13, 2025 07:31AM BridgeBio Pharma Inc. (BBIO): First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
May 13, 2025 07:30AM First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
May 12, 2025 07:30AM BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Fa
May 7, 2025 07:30AM BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
Apr 29, 2025 04:01PM BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
Apr 28, 2025 05:00AM BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
Apr 22, 2025 07:30AM BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
Apr 11, 2025 04:01PM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 31, 2025 10:00AM BridgeBio Pharma (BBIO) Reports Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Mar 31, 2025 10:00AM Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Mar 27, 2025 07:00AM BridgeBio Pharma (BBIO) Announces Beyonttra Approved in Japan to Treat ATTR-CM
Mar 27, 2025 07:00AM Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
Mar 24, 2025 07:30AM BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Session
Mar 21, 2025 04:00PM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 17, 2025 04:01PM BridgeBio Pharma Inc. (BBIO) appoints Thomas Trimarchi as CFO
Mar 17, 2025 04:01PM BridgeBio Announces CFO Succession
Feb 20, 2025 07:30AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
Feb 13, 2025 04:01PM BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
Feb 11, 2025 09:22AM BridgeBio Pharma Inc. (BBIO) Announces BEYONTTRA Approved by the European Commission to Treat ATTR-CM
Feb 11, 2025 09:21AM BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
Jan 13, 2025 11:00AM BridgeBio Pharma Inc. (BBIO) Announces Commercial Progress, Program Updates, and 2025 Milestones
Jan 13, 2025 11:00AM BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
Jan 8, 2025 07:30AM BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
Dec 13, 2024 07:19AM BridgeBio Pharma's (BBIO) Acoramidis Receives Positive CHMP Opinion
View Older Stories